Positions

Overview

  • Dr. Krontiras, a breast surgical oncologist, is the Medical Director of the UAB Multidisciplinary Breast Clinic, a clinic in which medical oncologists, surgeons and radiation oncologists work together to see approximately 450 new breast cancer cases each year. She is the Co-Director of the Lynne Cohen Preventive Care Program for Women's Cancers at UAB and the Co-Director of the Breast Cancer Prevention and Risk Assessment Clinic. In her role as Assistant Chief Medical Officer for Ambulatory Quality and Patient Safety for UAB Medicine, she participates in quality improvement and quality assurance activities related to delivery of high quality and cost-effective care, including analysis and regular review of ambulatory quality outcomes, and data and development of improvements in clinical and operational processes.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose and Steady State Pharmacokinetics Study of 9cUAB30 in Healthy Volunteers. 2019
    2019 Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristics 2019
    2019 The impact of breast lumpectomy tray utilization on cost savings 2019
    2018 Treatment patterns for ductal carcinoma in situ with close or positive mastectomy margins 2018
    2018 Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely® Campaign 2018
    2018 A Structured Compensation Plan Improves But Does Not Erase the Sex Pay Gap in Surgery 2018
    2018 Breast Cancer Genetics and Indications for Prophylactic Mastectomy 2018
    2018 Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters 2018
    2017 NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer 2017
    2016 Translation of a tissue-selective rexinoid, UAB30, to the clinic for breast cancer prevention 2016
    2016 Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely ® Initiative 2016
    2016 Exploring effects of presurgical weight loss among women with stage 0-II breast cancer: Protocol for a randomised controlled feasibility trial 2016
    2016 Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors 2016
    2016 Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013 2016
    2016 Impact of American College of Surgeons Oncology Group Z11 on surgical training at an academic cancer center 2016
    2016 Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case–control and case–case analyses 2016
    2015 Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors 2015
    2015 Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors 2015
    2015 Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers 2015
    2015 Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: A behavioral weight loss intervention in overweight or obese breast cancer survivors 2015
    2015 Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology 2015
    2015 TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer 2015
    2015 The Use of Modified Four-Dimensional Computed Tomography in Patients with Primary Hyperparathyroidism: An Argument for the Abandonment of Routine Sestamibi Single-Positron Emission Computed Tomography (SPECT) 2015
    2014 S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy 2014
    2014 Socioeconomic disparities in breast cancer treatment among older women 2014
    2014 Fostering coordinated survivorship care in breast cancer: Who is lost to follow-up? 2014
    2014 Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer 2014
    2014 Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657) 2014
    2014 What is a clear margin in breast conserving cancer surgery? 2014
    2013 Comparative evaluation of [99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients: Results of two phase 3 trials 2013
    2013 Harvest for health gardening intervention feasibility study in cancer survivors 2013
    2013 Reducing breast cancer recurrence with weight loss, a vanguard trial: The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial 2013
    2013 Time-trends in survival in young women with breast cancer in a SEER population-based study 2013
    2013 How do i screen patients for breast cancer? 2013
    2012 LEAP: Lead, Excel, Achieve, Perform: A Report on the UHC Annual Conference 2011 2012
    2012 Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657 2012
    2012 Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) 2012
    2012 Locally advanced breast cancers are more likely to present as interval cancers: Results from the I-SPY 1 TRIAL (CALGB 150007/150012, acrin 6657, interSPORE trial) 2012
    2011 An update on the dosimetric analysis of concurrent radiation therapy and trastuzumab on early cardiac events. 2011
    2011 Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. 2011
    2011 Image-guided methods for biopsy of suspicious breast lesions 2011
    2011 Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy 2011
    2010 Early results of an endoscopic nipple-sparing mastectomy for breast cancer 2010
    2010 A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers 2010
    2010 Minimal disease in the sentinel lymph node: How to best measure sentinel node micrometastases to predict risk of additional non-sentinel lymph node disease 2010
    2010 Breast cancer risk reduction 2010
    2010 The surgical management of ductal carcinoma in situ 2010
    2010 Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer 2010
    2010 Less-than-standard treatment in rectal cancer patients: Which patients are at risk? 2010
    2009 Beta-human chorionic gonadotropin production associated with phyllodes tumor of the breast: An unusual paraneoplastic phenomenon 2009
    2009 Discussion 2009
    2009 Specimen radiographs assist in identifying and assessing resection margins of occult breast carcinomas 2009
    2009 Breast cancer screening and diagnosis: Clinical practice guidelines in oncology™ 2009
    2008 The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and Her2/neu status in breast carcinoma 2008
    2008 Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers 2008
    2006 Discussion 2006
    2006 Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. 2006
    2006 Breast cancer screening and diagnosis: Clinical practice guidelines in oncology™ 2006
    2004 Nuclear Localization of KLF4 Is Associated with An Aggressive Phenotype in Early-Stage Breast Cancer 2004
    2003 Axillary Lymph Node Status, but Not Tumor Size, Predicts Locoregional Recurrence and Overall Survival after Mastectomy for Breast Cancer 2003
    2003 When is sentinel node biopsy for breast cancer contraindicated? 2003
    2001 Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53 2001
    2001 Options for management of the axillary lymph nodes in breast cancer 2001
    2001 Who should not receive chemotherapy? Data from American databases and trials. 2001
    1999 Transforming growth factor α (TGF-α) expression in dysplastic oral leukoplakia: Modulation by 13-cis retinoic acid 1999
    1999 Fatty acid synthase expression is increased in neoplastic lesions of the oral tongue 1999
    1999 T1 and t2 squamous cell carcinoma of the oral tongue: Prognostic factors and the role of elective lymph node dissection 1999

    Chapter

    Year Title Altmetric
    2018 Diagnostic approach to breast abnormalities.  610-623. 2018
    2012 Diagnostic approach to breast abnormalities 2012

    Research Overview

  • Dr. Krontiras is a fellowship trained breast surgical oncologist with primary research interests in prevention and risk assessment of breast cancer, quality in cancer care, and outcomes of breast cancer treatment.

    Keywords - breast cancer, chemoprvention
  • Principal Investigator On

  • Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect  awarded by University of Wisconsin-Madison 2016 - 2019
  • XUAB 1769: Phase lb 9cUAB30 In Early Stage Breast Cancer to Evaluate Biologic Effect (Cost Reimbursable)  awarded by University of Wisconsin-Madison 2016 - 2019
  • A Randomized, Double-Blind, Phase I Dose-Escalation Study of the Novel Retinoid 9cUAB30  awarded by University of Wisconsin-Madison 2015 - 2017
  • Targeting Signal Transduction Pathways for the Treatment and Prevention of Breast Cancer  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER) 2012 - 2014
  • A Randomized Double-Blind, Phase I Dose-Escalation Study of the Novel Retinoid 9cUAB30  awarded by University of Wisconsin-Madison 2013 - 2014
  • A Phase III Randomized Study of Exemestane Versus Exemestane Placebo in Postmenopausal Women at Increased Risk for Breast Cancer  awarded by Queen's University 2009 - 2013
  • UAB 1052-TBCR020: The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Lobular Neoplasia of the Breast by Core Needle Biopsy  awarded by Johns Hopkins University 2011 - 2013
  • Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER) 2011 - 2012
  • A Randomized, Double-Blind, Single-Dose and Multi-Dose Study of the Novel Retinoid, 9cUAB30 to Determine Pharmacokinetics and Safety  awarded by University of Wisconsin-Madison 2011 - 2012
  • Follow-up Study of Breast Health Outcomes and Selected Biomarkers in Women at High Risk for Breast Cancer: The Serial Evaluation of Ductal Epithelium (SEDE) Clinical Trial  awarded by DR. SUSAN LOVE RESEARCH FOUNDATION 2011 - 2012
  • Private Grant  awarded by NEOPROBE CORPORATION 2010 - 2011
  • Private Grant  awarded by NEOPROBE CORPORATION 2008 - 2011
  • Investigator On

  • Role of Gut Microbe Composition in Psychosocial Symptom Response to Exercise Training in Breast Cancer Survivors  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression  awarded by Johns Hopkins University 2018 - 2023
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2019 - 2022
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE 2018 - 2020
  • TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progession  awarded by Duke University 2018 - 2020
  • Enabling A Paradigm Shift: A Preference-Tolerant RCT of Personalized vs Annual Screening of Breast Cancer (WISDOM)  awarded by QUANTUM LEAP HEALTH CARE 2018 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • ACRIN 6694: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (R14-020)  awarded by American College of Radiology Imaging Network 2015 - 2018
  • Racial Disparities: Pain in Women Treated for Breast Cancer  awarded by National Cancer Institute/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2017
  • Feasibility of Dual-Energy (DE) Contrast-Enhanced (CE) Digital Mammography to Detect Breast Cancer in Patients with Increased Breast Density (BI-RADS Category 3 or 4) (R13-151)  awarded by Association of University Radiologists 2014 - 2017
  • Prospective Study of MRI and Multi-Parameter Gene Expression Assay in Ductal Carcinoma in Situ (DCIS) (R15-037)  awarded by American College of Radiology Imaging Network 2015 - 2017
  • Exploring Effects of Weight Loss on Ductal Carcinoma In Situ  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953  awarded by Johns Hopkins University 2009 - 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Private Grant  awarded by LEIDOS BIOMEDICAL RESEARCH, INC. 2013 - 2014
  • Private Grant  awarded by Genentech 2007 - 2014
  • Tissue Resource Site (TSS) in Support of the The Cancer Genome Atlas (TCGA) Program - Admin Core  awarded by SAIC - FREDERICK 2013 - 2014
  • Education And Training

  • UAB Hospital, Internship 1995
  • UAB Hospital, Residency 2000
  • Northwestern Memorial Hospital, Postdoctoral Fellowship 2001
  • Full Name

  • Helen Krontiras
  • Fax

  • 205-975-5971